- Home
- NTIP vs CRIS Comparison
NTIP vs CRIS Comparison
Compare NTIP & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.34
HOLD
Current Price
$0.86
Company Overview
Basic Information| Metric | NTIP | CRIS |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 14.6M |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NTIP | CRIS |
|---|---|---|
| Price | $1.34 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 15.2K | ★ 119.5K |
| Earning Date | 02-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 7.69% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $1.16 | $0.96 |
| 52 Week High | $1.90 | $3.87 |
Technical Indicators
Market Signals| Indicator | NTIP | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 25.17 |
| Support Level | $1.32 | $0.96 |
| Resistance Level | $1.42 | $1.03 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 87.44 | 18.00 |
Price Performance
Historical Comparison NTIP
CRIS
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.